Adenocarcinoma: all 1,996 studies

Page 15 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.

• Fibroblast Before and After Neoadjuvant Chemo-radiotherapy in Patient With Locally Advanced Rectal AdenocarcinomaCompletedNCT02849158Not applicable
• Molecular Analysis of 150 Lung AdenocarcinomaStatus unknownNCT02843711
• Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation)TerminatedNCT02838966Not applicable
• Biological and Clinical Database for Pancreatic AdenocarcinomaActive, not recruitingNCT02818829
• Mechanisms of Cancerogenesis of Woodworkers AdenocarcinomasCompletedNCT02818231
• Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the PancreasStatus unknownNCT02817308Not applicable
• The Utility of Circulating Tumour Cells and Plasma microRNA in Esophageal AdenocarcinomaCompletedNCT02812680
• Prevalence of Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic AdenocarcinomaCompletedNCT02810730Not applicable
• NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate AdenocarcinomaTerminatedNCT02805894Phase 1/2
• Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung AdenocarcinomaStatus unknownNCT02804646Phase 4
• Serum and Peritoneal CEA and CA 19-9 for Gastric AdenocarcinomaCompletedNCT02801955
• Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model GenerationStatus unknownNCT02795650Phase 2
• LRP1 and Colon CancerStatus unknownNCT02788669
• A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI TherapyStatus unknownNCT02788058Phase 2
• Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyStatus unknownNCT02787447Phase 2
• Cancer-related Thromboembolic DiseaseStatus unknownNCT02785757Not applicable
• Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot StudyTerminatedNCT02782182Phase 1
• Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity ScoreStatus unknownNCT02781285
• Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control TrialStatus unknownNCT02780921Phase 3
• Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal AdenocarcinomaCompletedNCT02775786Not applicable
• CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal TumorsTerminatedNCT02757391Phase 1
• Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph NodesStatus unknownNCT02754180Phase 2
• Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic CancerCompletedNCT02749136Phase 2
• Near-infrared Image Guided Surgery in Pancreatic AdenocarcinomaTerminatedNCT02743975Phase 1/2
• Minimally Invasive Sweet Esophagectomy for Patients With Siewert Type II Adenocarcinoma of the Esophagogastric JunctionStatus unknownNCT02741778Not applicable
• Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the PancreasStatus unknownNCT02739633Phase 2
• A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation TestStatus unknownNCT02738684
• Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver MetastasesTerminatedNCT02709811Phase 1/2
• Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)TerminatedNCT02707328Phase 1
• A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas CancerStatus unknownNCT02707315Early Phase 1
• Tarceva With or Without Apatinib in the Advanced Lung AdenocarcinomaStatus unknownNCT02704767Phase 2
• Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFRStatus unknownNCT02691871Phase 1
• Resilience and Exercise in Advanced Cancer TreatmentCompletedNCT02680990Not applicable
• Vitamin Supplementation in NSCLC Patients on Pemetrexed Based ChemotherapyCompletedNCT02679443Not applicable
• Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
• Study of SBP-101 in Pancreatic CancerCompletedNCT02657330Phase 1
• Intraoperative Imaging of Pulmonary AdenocarcinomaWithdrawnNCT02653612Phase 1
• TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsTerminatedNCT02650635Phase 1
• Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal MalignanciesTerminatedNCT02638909Phase 2
• Carnoy's Solution Versus Formalin in Rectal and Gastric Cancer Specimens Following: a Randomized TrialCompletedNCT02629315Not applicable
• Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic AnalysisCompletedNCT02628951Phase 2
• Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac CancerStatus unknownNCT02628665Phase 3
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung AdenocarcinomaTerminatedNCT02621333Phase 2
• Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic CancerCompletedNCT02620800Phase 1
• Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedNCT02620423Phase 1
• PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric AdenocarcinomaCompletedNCT02615730Phase 1/2
• Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTCCompletedNCT02610764Not applicable
• Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid TumorsStatus unknownNCT02607826Not applicable
• Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate BrachytherapyWithdrawnNCT02597894Not applicable
• Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic AdenocarcinomaWithdrawnNCT02592395Phase 1
• Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionCompletedNCT02578368Phase 3
• Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerWithdrawnNCT02575508Phase 1/2
• A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesCompletedNCT02572687Phase 1
• Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent ChemoradiotherapyWithdrawnNCT02570529Phase 4
• Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric JunctionCompletedNCT02564367Phase 1/2
• Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to RadiochemotherapyTerminatedNCT02551458Phase 2/3
• Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic CancerCompletedNCT02550327Early Phase 1
• Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung CancerCompletedNCT02535325Phase 1
• A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPCStatus unknownNCT02525068Phase 2
• Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02518802Phase 3
• Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of PancreasStatus unknownNCT02514928Phase 3
• Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic AdenocarcinomaCompletedNCT02514421Phase 1
• Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) CancerStatus unknownNCT02512380Phase 3
• Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the EsophagusActive, not recruitingNCT02509286Phase 3
• Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic AdenocarcinomaCompletedNCT02504333Phase 1/2
• Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel AdenocarcinomaStatus unknownNCT02502370Phase 3
• Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of LungCompletedNCT02498860Phase 2
• S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric AdenocarcinomaCompletedNCT02495493Phase 2
• The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFRActive, not recruitingNCT02493582Phase 2
• Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant ChemoradiotherapyStatus unknownNCT02490709Phase 2
• Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic AdenocarcinomasCompletedNCT02487836Phase 2
• NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric AdenocarcinomaStatus unknownNCT02486601Phase 2
• Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal CancerTerminatedNCT02473094Phase 2
• PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate CancerCompletedNCT02472275Phase 1
• Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the LungWithdrawnNCT02466568Phase 1/2
• Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line ChemotherapyTerminatedNCT02449655Phase 2
• Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line ChemotherapyCompletedNCT02448329Phase 2
• Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line ChemotherapyCompletedNCT02448290Phase 2
• Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line TreatmentCompletedNCT02447406Phase 1/2
• Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line TreatmentCompletedNCT02447380Phase 2
• Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by SurgeryStatus unknownNCT02446366Not applicable
• Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaActive, not recruitingNCT02446093Phase 2
• Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter TrialCompletedNCT02440958Phase 2
• A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line ChemotherapyCompletedNCT02435108Phase 2
• Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT02426281Phase 2
• A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerCompletedNCT02426034Phase 4
• Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOXTerminatedNCT02425683Phase 2
• Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal CarcinomatosisTerminatedNCT02420509
• Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal CancerCompletedNCT02415101Not applicable
• Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression AssaysTerminatedNCT02407561
• Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast CancerTerminatedNCT02404506Phase 2
• Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With ChemotherapyTerminatedNCT02404363Phase 3
• Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaStatus unknownNCT02399566Phase 4
• Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic CancerCompletedNCT02394535Phase 1
• Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic AdenocarcinomaCompletedNCT02391662Phase 2
• Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）CompletedNCT02390947Phase 3
• Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric AdenocarcinomaCompletedNCT02370849Phase 2
• OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic AdenocarcinomaCompletedNCT02368860Phase 1

← Adenocarcinoma overview